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concentrations doubled owing to a 1-standard deviation 
(SD) decrease in urine trigonelline levels, or increased by 29–
50% in relation to a 1-SD decrease in urine pyroglutamate, 
acetone and hippurate levels.  Conclusion: Our findings in 
humans confirmed the metabolic effects of circulating 3,5-T 2 
on glucose and lipid metabolism, oxidative stress and en-
hanced drug metabolism as postulated before based on in-
terventional pharmacological studies in rodents. Of note, 
3,5-T 2 exhibited a unique urinary metabolic profile distinct 
from previously published results for the classical thyroid 
hormones.  © 2015 European Thyroid Association
Published by S. Karger AG, Basel 
 Introduction 
 During the last decade the concepts of thyroid hor-
mone (TH) action underwent a sustainable gain in com-
plexity  [1–3] . New mechanisms of action concerning the 
classical TH –  L -thyroxine (T 4 ) and 3,3 ′ ,5-triiodo- L -thy-
ronine (T 3 ) – became obvious, including biological effects 
of nonclassical TH such as tetraiodothyroacetic acid  [3, 
4] and 3,5-diiodo- L -thyronine (3,5-T 2 )  [4] , the putative 
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 Abstract 
 Context: 3,5-Diiodo- L -thyronine (3,5-T 2 ) is a thyroid hor-
mone metabolite which exhibited versatile effects in rodent 
models, including the prevention of insulin resistance or
hepatic steatosis typically forced by a high-fat diet. With re-
spect to euthyroid humans, we recently observed a putative 
link between serum 3,5-T 2 and glucose but not lipid metabo-
lism.  Objective: The aim of the present study was to widely 
screen the urine metabolome for associations with serum 
3,5-T 2 concentrations in healthy individuals.  Study Design 
and Methods: Urine metabolites of 715 euthyroid partici-
pants of the population-based Study of Health in Pomerania 
(SHIP-TREND) were analyzed by  1 H-NMR spectroscopy. Mul-
tinomial logistic and multivariate linear regression models 
were used to detect associations between urine metabolites 
and serum 3,5-T 2 concentrations.  Results: Serum 3,5-T 2 con-
centrations were positively associated with urinary levels of 
trigonelline, pyroglutamate, acetone and hippurate. In de-
tail, the odds for intermediate or suppressed serum 3,5-T 2 
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deiodination product of T 3 in vivo. 3,5-T 2 exhibited re-
markable metabolic effects when used as a pharmacolog-
ical agent in animal studies. Administered to hypothyroid 
rats, 3,5-T 2 prevented and even reversed the severe con-
sequences typically induced by a high-fat diet, like weight 
gain, insulin resistance or hepatic steatosis  [5–7] . The re-
sponsible mechanisms include improvement of the blood 
lipid profile through the stimulation of β-oxidation of 
free fatty acids (FFA) and mitochondrial uncoupling, as 
well as depression of gluconeogenesis in hepatocytes  [5, 
8] . Therefore, 3,5-T 2 appears to act in a distinctively dif-
ferent mode compared to T 3 .
 Beside pharmacological studies in rodents, the knowl-
edge about circulating 3,5-T 2 in humans is sparse. Early 
human studies in small and selected cohorts reported as-
sociations with chronic renal disease, liver cirrhosis or sep-
sis  [9–11] . Most of these early data stem from observation-
al analyses and detection of 3,5-T 2 in human serum em-
ploying polyclonal antibody-based immunoassays which 
resulted in a wide spectrum of reported 3,5-T 2 serum con-
centrations spanning almost two orders of magnitude [for 
a review see  12 ]. Development and application of a mono-
clonal antibody-based chemiluminescent immunoassay 
recently revealed serum 3,5-T 2 concentrations in the range 
of 0.2–0.5 n M in healthy individuals  [12] . These 3,5-T 2 val-
ues showed no correlation to serum T 4 or T 3 concentra-
tions in healthy or T 4 -substituted individuals, indicating 
that serum 3,5-T 2 has a metabolic fate independent of that 
related to T 4 and T 3 . Using this assay we recently observed 
a putative link between serum 3,5-T 2 and glucose but not 
lipid metabolism in euthyroid humans  [13] . 
 Expanding these initial rodent experimental and hu-
man observational findings on the metabolic effects of 
3,5-T 2 , high-throughput techniques like proton nuclear 
magnetic resonance ( 1 H-NMR) spectroscopy can be used 
 [14] to collect further information on the metabolic ac-
tions of 3,5-T 2 .  1 H-NMR spectroscopy attempts to give a 
comprehensive view of small-molecule metabolites pres-
ent in various biofluids, thus providing a more sensitive 
tool than classical clinical markers  [15] . Urine, which is 
readily available, as a downstream product of human me-
tabolism can especially mirror the impact of genetic de-
terminants, environmental factors, personal behavior, 
nutrition and therapeutic intervention  [16] . Despite these 
advantages, the use of metabolomics in the investigation 
of TH (metabolite) action is, to the best of our knowledge, 
limited to intervention studies in rodents  [17–21] and, 
with the exception of a recent study on the relation be-
tween TH status and serum metabolites  [22] , completely 
lacking in humans. Therefore, the present study was de-
signed to gain further insights into the metabolic profiles 
associated with circulating 3,5-T 2 by means of urine me-
tabolomics in a large euthyroid study population.
 Material and Methods 
 Study Population 
 SHIP-TREND is the second cohort of the Study of Health in 
Pomerania (SHIP), a population-based research project in West 
Pomerania, a rural region in north-east Germany  [23] . A stratified 
random sample of 8,826 adults aged 20–79 years was drawn from 
population registries. Sample selection was facilitated by the cen-
tralization of local population registries in the Federal State of 
Mecklenburg-West Pomerania. The stratification variables were 
age, sex and city/county of residence. General baseline examina-
tions were conducted between 2008 and 2012. Out of all the invita-
tions, 4,420 individuals choose to participate (representing a 50.1% 
response rate). The study was approved by the local ethics com-
mittee and conformed to the principles of the declaration of Hel-
sinki. For a specific SHIP-TREND subsample that encompasses 
1,000 participants without self-reported diabetes who underwent 
an oral glucose tolerance test, a more extensive phenotyping was 
performed including, for example, additional laboratory measure-
ments and metabolome analyses. This most comprehensively ana-
lyzed subsample of SHIP was chosen to ensure a maximum avail-
ability of clinically relevant information.
 Of these participants, 995 were characterized by urine  1 H-
NMR spectra. Furthermore, we excluded subjects with one of the 
following conditions (overlaps existed): low urinary creatinine 
concentrations (<2 mM, n = 50), missing values (n = 108) or values 
more than twice the standard deviation (SD) away from mean se-
rum 3,5-T 2 concentrations (>2.13 n M , n = 15), use of thyroid med-
ications (ATC code H03A or H03B, n = 98) or serum thyrotropin 
(TSH) levels outside the reference range (0.30–3.59 mU/l, n = 51). 
Ultimately, 715 subjects, aged between 21 and 81 years, were in-
cluded in the present analysis. 
 Measurements 
 Each SHIP-TREND participant underwent standardized med-
ical examinations, blood sampling and an extensive computer-aid-
ed personal interview. Data on sociodemographic characteristics 
and medical histories were collected. Waist circumference (WC) 
was measured by an inelastic tape between the lower rib margin 
and the iliac crest in the horizontal plane.
 Blood and urine samples (fasting  ≥ 8 h) were collected between 
6.00 a.m. and 7.00 p.m. Blood samples were drawn from the cubi-
tal vein of subjects in the supine position. Both urine and blood 
samples were analyzed immediately or stored at –80   °   C. Serum 
TSH concentrations were measured using an immunoassay (Di-
mension VISTA, Siemens Healthcare Diagnostics, Eschborn, Ger-
many) with a functional sensitivity of 0.005 mU/l. Serum 3,5-T 2 
concentrations were measured with a recently developed mono-
clonal antibody-based chemiluminescence immunoassay  [12] . 
The functional sensitivity of the assay was specified as 0.2 n M . The 
interassay variation was between 5.6 and 12.9%. The working 
range was declared as 0.2–10 n M 3,5-T 2 . Urine creatinine con-
centrations were measured using the Jaffé method (Dimension 
VISTA, Siemens Healthcare Diagnostics). 
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 1 H-NMR Spectroscopic Analysis of Urinary Specimens 
 After thawing, urine specimens were centrifuged for 5 min at 
3,000  g and the supernatant was used for spectroscopic analysis. 
To this purpose, 450 μl of urine were mixed with 50 μl of phosphate 
buffer in order to stabilize the urinary pH at 7.0 (±0.35). The phos-
phate buffer was prepared with D 2 O and contained sodium TSP 
[3-trimethylsilyl-(2,2,3,3-D4)-1-propionate] as the reference. 
Spectra were recorded at the University Medicine Greifswald, Ger-
many, on a Bruker DRX-400 NMR spectrometer (Bruker BioSpin 
GmbH, Rheinstetten, Germany) operating at a  1 H frequency of 
400.13 MHz and equipped with a 4-mm selective inverse flow 
probe (FISEI, 120 μl active volume) with a z-gradient. Specimens 
were automatically delivered to the spectrometer via flow injec-
tion. The acquisition temperature was set to 300°K. A standard 
one-dimensional  1 H-NMR pulse sequence with suppression of the 
water peak (NOESYPREAST) was used: relaxation delay (RD) – 
P(90°) – 4 μs – P(90°) – mixing time (tm) – P(90°) – acquisition of 
the free induction decay (FID). The nonselective 90-degree hard 
pulse P(90°) was adjusted to 9.4 μs. The RD, the tm and the acqui-
sition time were set to 4 s, 100 ms and 3.96 s, respectively, resulting 
in a total recycle time of  ∼ 8.0 s. Low-power continuous-wave ir-
radiation on the water resonance at a field strength of  ∼ 25 Hz was 
applied during RD and tm for presaturation. After the application 
of 4 dummy scans, 64 FIDs were collected into 65,536 (64 K) com-
plex data points using a spectral width of 20.689 parts per million 
(ppm). FIDs were multiplied with an exponential function corre-
sponding to a line broadening of 0.3 Hz before Fourier transforma-
tion. Spectra were manually phase and baseline corrected and au-
tomatically referenced to the internal standard (TSP, 0.0 ppm) 
within TopSpin 1.3 (Bruker BioSpin). 
 The Fourier-transformed and baseline-corrected NMR spectra 
were manually annotated by spectral pattern matching using Che-
nomx NMR Suite 7.0 (Chenomx Inc., Edmonton, Alta., Canada) 
to deduce absolute urinary concentrations of 47 metabolites; sub-
sequently, the NMR data was reduced to these metabolites  [24] . 
Online supplementary figure S2 (for all online suppl. materials,
see www.karger.com/doi/10.1159/000381308) contains example 
spectra as well as annotated signals for relevant metabolites in the 
present analysis. To account for diurnal urine dilution, metabolite 
concentrations were normalized by urine creatinine levels and are 
reported as millimoles per mole of creatinine. To reflect the rela-
tionships between metabolites, associated with circulating 3,5-T 2 , 
their ratios were calculated, resulting in 1,035 additional variables.
 Statistical Analysis 
 Continuous data are expressed as the median (1st; 3rd quartile), 
and nominal data as a percentage. For bivariate statistics the Wil-
coxon rank sum test (continuous data) or χ 2 test (nominal data) 
were used to compare men and women. Metabolite and metabolite 
ratios, as well as 3,5-T 2 concentrations, were log-transformed to 
achieve a normal distribution. Furthermore, metabolite/ratio levels 
were scaled according to their SD to facilitate comparison between 
associations. Since about a third of the study population exhibited 
3,5-T 2 concentrations below the detection limit of the used assay 
(0.2 n M ) but distinctly higher than blank values of the standard 
curve, subjects were subdivided into three groups according to their 
3,5-T 2 concentrations: <0.2 n M (n = 255) but distinct from zero, 
0.2–0.33 n M (n = 230) and >0.33 n M (n = 230). Subsequently, mul-
tinomial regression models with metabolite/ratio levels as expo-
sures and 3,5-T 2 groups as outcome were performed. After the ex-
clusion of participants with zero values for each metabolite/ratio 
and 3,5-T 2 concentrations below 0.2 n M , multivariate linear models 
with 3,5-T 2 concentrations as the continuous outcome were per-
formed. All models were adjusted for age, sex and WC, as well as 
for TSH concentrations in sensitivity analyses. In a sensitivity anal-
ysis the influence of prior excluded subjects with high serum 3,5-T 2 
or TSH concentrations outside the reference range (n = 757; n = 
267 with serum 3,5-T 2 <0.2 n M ) was tested to analyze the influence 
of an altered thyroid state. A p value <1.1 × 10 –3 (Bonferroni cor-
rection) for metabolites or <4.6 × 10 –5 (Bonferroni correction) for 
metabolite ratios was considered as statistically significant. Statisti-
cal analyses were performed using SAS version 9.3 (SAS statistical 
software, SAS Institute Inc., Cary, N.C., USA) and R 3.0.1 (R Foun-
dation for Statistical Computing, Vienna, Austria).
 Results 
 The general characteristics for men and women are 
summarized in  table 1 . Women were more often never 
smokers and had lower values of WC, whereas serum 
TSH levels were higher compared to men. No sex-specif-
ic differences regarding age or 3,5-T 2 concentrations
became obvious. Creatinine-standardized urine metabo-
lites exhibited a sex-specific phenotype, with mostly high-
er values among women (online suppl. table S1). 
 Multinomial logistic regression models revealed sev-
eral metabolites, including pyroglutamate, hippurate, ac-
etone, formate and trigonelline, significantly associated 
with 3,5-T 2 ( fig. 1 ,  2 ;  table 2 ). In detail, the odds for sup-
 Table 1.  General characteristics of the study population
Characteristics Male
(n = 351)
Female
(n = 364)
p1
Age, years 50.2 (38.6; 60.8) 48.1 (40.2; 59.5) 0.70
Smoking status, % <0.01
Never 32.4 52.5
Former 43.2 28.0
Current 24.4 19.5
Physical activity, % 0.74
>1 h/week 50.7 51.9
<1 h/week 49.3 48.1
WC, cm 94.0 (86.2; 102.3) 81.5 (73.7; 90.1) <0.01
TSH, mU/l 1.11 (0.79; 1.47) 1.29 (0.91; 1.76) <0.01
3,5-T2, nM 0.24 (0.20; 0.38) 0.25 (0.20; 0.36) 0.91
Urine creatinine, mM 12.5 (7.1; 17.0) 6.5 (4.0; 11.0) <0.01
 Data are expressed as median (25th; 75th percentile). 
1 The Wilcoxon rank sum test for continuous and the χ2 test for 
categorical data were used for comparison.
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pressed (<0.2 n M ) or intermediate (0.2–0.33 n M ) serum 
3,5-T 2 concentrations doubled owing to a 1 SD decrease 
in logarithmic trigonelline levels. Furthermore, 29–50% 
increased odds for suppressed or intermediate serum 3,5-
T 2 concentrations were related to a 1 SD decrease in urine 
pyroglutamate, acetone and hippurate levels ( fig.1 ,  2 ;
 table 2 ). Multivariate linear models confirmed these find-
ings, even if only the positive association with trigonelline 
reached the corrected statistical significance ( fig. 3 ). This 
association was confirmed by the high number of signifi-
cantly associated metabolite ratios regarding trigonelline 
( fig. 3 ). 
 Adjustment for TSH levels in multinomial logistic and 
linear regression models did not change the above-men-
tioned associations ( fig. 3 ; online suppl. fig. S1). Interest-
ingly, the inclusion of subjects with extreme serum 3,5-T 2 
or TSH concentrations outside the reference range led to 
a general loss of significance (data not shown). Regard-
less, the associations towards trigonelline and hippurate 
remained significant. 
 Fig. 1. Results for 3,5-T2 from multinomial logistic regression (ref. 
>0.33 n M ) models adjusted for age, sex and WC. p values for the 
suppressed (<0.20 n M ) or intermediate (0.20–0.33 n M ) group are 
colored blue and orange, respectively. Each line and column rep-
resents one metabolite; the diagonal contains results for single me-
tabolites divided into triangles for each hormone, all other boxes 
represent the respective ratio; thick-framed triangles indicate sig-
nificant metabolites: p meta = 0.05/47 = 1.1 × 10 –3 ; thick-framed 
squares indicate significant ratios: p all = 0.05/1,082 = 4.6 × 10 –5 
(accordingly corrected for multiple testing). Ratios with creatinine 
were not included in the analysis (colored gray), since all metabo-
lites were normalized on creatinine. 
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 Fig. 2. Box plots of levels of urine pyroglutamate, hippurate, acetone and trigonelline by 3,5-T2 concentration. 
The black triangles indicate group means. Asterisks ( * ) indicate a significant odds ratio compared to the highest 
group from the multinomial logistic regression analysis (see table 2). 
 Table 2.  Significant associations between urinary metabolites and serum 3,5-T2 concentrations
Metabolites per
SD decrease
n SD  OR (95% CI)1 (ref. >0.33 nM) n SD β (95% CI)2 p
<0. 2 nM p 0.2 – 0.33 nM p
Pyroglutamate 656 0.24 1.36 (1.11; 1.65) <0.01 1.44 (1.17; 1.77)a <0.01 428 0.26 –0.059 (–0.102; –0.016) <0.01
Hippurate 715 0.84 1.44 (1.19; 1.76)a <0.01 1.31 (1.07; 1.59) <0.01 460 0.83 –0.054 (–0.098; –0.011) 0.01
Acetone 561 0.73 1.29 (1.04; 1.59) 0.02 1.50 (1.20; 1.88)a <0.01 363 0.69 –0.057 (–0.104; –0.010) 0.02
Trigonelline 665 0.88 2.46 (1.96; 3.08)a <0.01 2.11 (1.68; 2.65)a <0.01 434 0.87 –0.152 (–0.194; –0.112)a <0.01
 All metabolites were in relation to creatinine. ref. = Reference tertile. a p < 0.05/47 = 1.1 × 10 – 3. 
1 Multinomial logistic regression models adjusted for age, sex and WC. 2 Multivariate linear regression models adjusted for age, sex 
and WC.
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 Discussion 
 The present study screened the human urine metabo-
lite profile assessed by  1 H-NMR spectroscopy for associa-
tions towards serum 3,5-T 2 concentrations. As discussed 
below, our results regarding trigonelline, pyroglutamate 
or acetone support and extend previously observed asso-
ciations between 3,5-T 2 and glucose or lipid metabolism 
as demonstrated by various animal models  [4, 5, 8, 25–
29] . Furthermore, we observed thyromimetic, but TSH 
independent, associations regarding hippurate and pyro-
glutamate, as observed in recent animal studies  [17, 19] . 
 Among all associated metabolites, trigonelline exhib-
ited the strongest association with 3,5-T 2 and remains sig-
nificant even after adjustment for serum or urine glucose 
levels, possibly confounding the association. The origin 
of urine trigonelline could either be exogenous, as food 
ingredients, or endogenous as a product of niacin me-
tabolism  [30, 31] . Administration of trigonelline reduced 
blood glucose levels by improving insulin sensitivity after 
 Fig. 3. Results for  3,5-T 2 colored according to p values form mul-
tivariate linear regression models adjusted for age, sex and WC 
(model 1; blue) and further for serum TSH levels (model 2; or-
ange). Each line and column represents one metabolite; the diago-
nal contains results for single metabolites, all other boxes represent 
the respective ratio; light blue frames indicate significant metabo-
lites: p meta = 0.05/47 = 1.1 × 10 –3 ; dark blue frames indicate sig-
nificant ratios: p all = 0.05/1,082 = 4.6 × 10 –5 (accordingly corrected 
for multiple testing). Ratios with creatinine were not included in 
the analysis (colored gray), since all metabolites were normalized 
on creatinine. 
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experimental induction of type 2 diabetes mellitus  [32–
34] . Similar effects were reported for 3,5-T 2 when used as 
a pharmacological agent to prevent insulin resistance 
forced by a high-fat diet  [5] . Further animal studies  [27, 
35, 36] confirmed the antidiabetic effect of both trigonel-
line and 3,5-T 2 , revealing protective effects on impaired 
kidney function and structure, which represents a severe 
sequelae of type 2 diabetes mellitus. Taken together, 3,5-
T 2 and trigonelline were linked to glucose metabolism, 
exhibiting the potential to improve glucose homeostasis 
in the case of diminished insulin sensitivity. Since a de-
crease in 3,5-T 2 concentrations was associated with a de-
crease in urine trigonelline levels, a mutual interaction or 
interdependency appears possible. In this context previ-
ous reports on inhibition of T 3 production by administra-
tion of fenugreek seed extracts in rodents are of interest. 
These trigonelline-rich extracts inhibit T 3 production 
from T 4 concomitant to decreasing hepatic superoxide 
dismutase activity, but leaving lipid peroxidation and cat-
alase activity unaltered  [37] , thus supporting links be-
tween TH status, glucose metabolism and trigonelline, 
which still need to be unraveled in detail. 
 Glucose metabolism was further related to 3,5-T 2 
via stimulation of glucose-6-phosphate dehydrogenase 
(G6PD)  [38] , a key enzyme of the pentose phosphate 
pathway. G6PD catalyzes the conversion of  D -glucose-
6-phosphate to 6-phospho- D -glucono-1,5-lactone, there-
by producing nicotinamide adenine dinucleotide phos-
phate (NADPH). NADPH in turn is necessary for the re-
duction of oxidized glutathione, to restore intracellular 
levels of reduced glutathione after response to oxidative 
stress. Beside this redox cycle, glutathione synthesis is as-
sured by the γ-glutamyl cycle, which at least in astrocytes 
 [39] was assumed to be stimulated by TH. The γ-glutamyl 
cycle involves the formation of pyroglutamate (5-oxo-
proline), which could be converted to glutamate and 
hence integrated in glutathione synthesis, but its conver-
sion depends on glutathione synthase activity. Depressed 
glutathione synthase activity leads to a rise of pyrogluta-
mate excretion in blood and subsequently in urine  [40] . 
In this context, the observed positive association between 
3,5-T 2 and urine pyroglutamate levels might point to-
wards a link between 3,5-T 2 and antioxidant defense, sup-
porting observations from a recent proteomics study 
 [29] . Shifts in hepatic cysteine flux, altered TH homeosta-
sis and lipid metabolism have recently been observed in a 
study on the hepatic profile in mice with suboptimal he-
patic and systemic expression of enzymes involved in cel-
lular redox regulation due to mild selenium deficiency 
 [20] .
 Acetone is a ketone body derived by a spontaneous de-
carboxylation of acetoacetate, which in turn is derived 
from acetyl-CoA. Generally, acetyl-CoA serves as sub-
strate for the tricarboxylic acid cycle by condensing with 
oxaloacetate. In a state of low oxaloacetate levels, acetyl-
CoA is redirected to ketogenesis. This displays a switch in 
energy metabolism from glucose to FFA utilization. Urine 
ketone body levels were considered as markers for mito-
chondrial β-oxidation of FFAs  [41] . The positive associa-
tion between 3,5-T 2 concentrations and urine acetone lev-
els observed in our study is in concordance with several 
animal studies  [8, 25, 26] showing rapid enhanced FFA 
transportation and subsequent oxidation in the mito-
chondria of skeletal muscle and hepatocytes of hypothy-
roid rats treated with 3,5-T 2 . As the molecular target car-
nitine palmitoyltransferase-1 (CPT1) was identified, 
which constitutes the main gateway for FFAs to mito-
chondria  [8, 25] . Of note, related enzymes, including 
CPT1, were reported to be altered by 3,5-T 2 treatment in 
the liver of rats fed with a high-fat diet  [29] . Furthermore, 
enhanced ketogenesis following TH metabolite adminis-
tration was even observed in two previous studies, where 
3-iodothyronamine (3-T1AM) treatment results in elevat-
ed serum and urine ketone bodies  [21, 42] . This observa-
tion might support the hypothesis that 3,5-T 2 might be 
(one of) the precursor(s) of biosynthesis of 3-T1AM  [12, 
43, 44] . Consequently, it should be considered to expand 
the concept of TH action on (lipid) metabolism to meta-
bolically active TH derivatives originating from the clas-
sical TH T 4 and T 3 by further deiodination and decarbox-
ylation in target tissues such as liver, skeletal muscle and 
adipose tissue.
 In concordance with this hypothesis, we observed an 
association with urine levels of hippurate, which were 
shown to be elevated in the case of experimental induc-
tion of hypothyroidism in rats  [19] . Since previous work 
 [12] suggested unaltered serum 3,5-T 2 concentrations in 
hypothyroidism, a decreased ratio of the putative precur-
sor T 4 (T 3 ) and 3,5-T 2 could account for this observation. 
However, the relation between serum fT 4 as well as TSH 
and 3,5-T 2 concentrations in humans is not yet complete-
ly understood. Moreover, in the present study the inclu-
sion of subjects with abnormal serum 3,5-T 2 or TSH con-
centrations led to weaker associations, suggesting differ-
ing roles of serum 3,5-T 2 on intermediary metabolism in 
different thyroid states. It is worth noting that, besides 
hippurate, 3,5-T 2 exhibited a unique associated urinary 
metabolic profile in comparison with TSH and fT 4  [19] .
 Our study has some strengths and some potential lim-
itations. Metabolomics is a powerful tool for endocrine 
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research, since it has the capability of jointly capturing 
versatile influences, like genetics or health behavior, in 
intermediate phenotypes. These intermediate pheno-
types even enable the analysis of effects of moderate en-
docrine actors. In contrast to the previously performed 
interventional studies on animals, the present study is 
limited by the cross-sectional and agnostic design, where-
by no prediction of time courses and detection of inter-
vention effects are possible. Moreover, the functional sen-
sitivity of the assay used to measure serum 3,5-T 2 repre-
sented a strong limitation in the statistical analysis, since 
one third of study participants (n = 255) exhibited con-
centrations below this detection limit. Our findings 
should therefore be regarded as hypothesis generating. It 
is widely accepted that  1 H-NMR spectroscopy is ham-
pered by lower sensitivity in comparison with chromato-
graphic coupled mass spectrometry. Hence, we expect 
that further metabolites and subsequent pathways are as-
sociated with 3,5-T 2 concentrations. Especially in epide-
miological research, urine metabolomics by means of  1 H-
NMR spectroscopy has the advantage of robust and re-
producible measurements of very large sample numbers. 
 In conclusion, we observed, for the first time, associa-
tions between urine metabolites and serum 3,5-T 2 . The 
detected metabolites are related to glucose (trigonelline) 
and lipid metabolism (acetone), as well as the response to 
oxidative stress or drug metabolism (pyroglutamate), and 
are in concordance with previously published liver pro-
teome analyses  [29] . Interestingly, some of the associa-
tions (hippurate and pyroglutamate) were recently re-
ported for rodent models of experimental hypothyroid-
ism, whereas the majority of associations reported here 
constitute a new and unique association to 3,5-T 2 . In con-
cordance with several animal studies, our findings em-
phasize the need to consider the extension of classical TH 
action by additional metabolically active TH metabolites, 
such as 3,5-T 2 . Further studies with complementary me-
tabolomics tools like mass spectrometry and the conduc-
tion of other biofluids, such as serum, could provide fur-
ther insight into the role of serum 3,5-T 2 in human me-
tabolism.
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